Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association. 2018;16(3):417 - 426.

Publication Type:

Journal Article

Source:

Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, Volume 16, Issue 3, p.417 - 426 (2018)

Keywords:

DAA, Direct-Acting Antiviral, Pangenotypic, Short-duration
Top